Search the Newsreel

VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger

VYNE Therapeutics has approved a 1-for-50 reverse stock split and declared a special cash dividend of $17.3 million, or approximately $0.40242 per share, in anticipation of its merger with Yarrow Bioscience. The combined company, to be named Yarrow Bioscience, Inc., will trade on Nasdaq …

Frontier tech research, news & data

The document provides an 8-K filing from VYNE Therapeutics Inc. dated July 20, 2026, accessible via SEC EDGAR. It also highlights a research report on fuel-cell deployments at U.S. data centers, detailing 154 MW of operating capacity and 6.31 GW in proposed projects across …

Vyne Therapeutics holds shareholder special meeting on merger proposals

Vyne Therapeutics held a special shareholder meeting on July 16, 2026, where shareholders approved the issuance of shares to Yarrow holders as part of a merger agreement. They also adopted a reverse stock split, increased authorized common shares to 300 million, and approved the …

VYNE Therapeutics (NASDAQ: VYNE) investors approve Yarrow merger

VYNE Therapeutics Inc. stockholders have approved key proposals related to its merger with Yarrow Bioscience, Inc. at a special meeting on July 16, 2026. Approvals included the issuance of VYNE common shares to Yarrow stockholders, a reverse stock split, an increase in authorized common …

VYNE Therapeutics (VYNE) investor reports 5.5M-share, 16.5% ownership stake

Zhang Xiaofan, a Hong Kong citizen residing in Shanghai, has reported a 16.5% ownership stake in VYNE Therapeutics Inc. This translates to beneficial ownership of 5,511,558 shares of VYNE common stock, over which Zhang Xiaofan holds sole voting and sole dispositive power. The disclosure …

VYNE Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline - Revenue Guidance Range

VYNE Q1 2026 Earnings: Significant EPS Beat Driven by Cost Controls - Diluted EPS Report

VYNE Therapeutics (VYNE) Edges Lower as Shares Test Key Support Near $0.65 - Volume Breakout Ideas

Vyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

VYNE Therapeutics Inc. (VYNE) Stock Price, Chart, News & Analysis

VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis